Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page

Director's Report to the National Advisory Council on Drug Abuse
September, 2001

Extramural Policy and Review Activities

Review Meetings

For this Council cycle, the Office of Extramural Affairs arranged and managed 23 review meetings for 373 applications in its standing committees, applications in conflict-of-interest with standing committees, and RFA submissions. There were an additional 13 reviews held for contract proposals, and one concept was reviewed.

The reviews for NIDA's chartered committees were held. These consist of NIDA-E (Treatment Review Committee), NIDA-F (Health Services Review Committee), NIDA-L (Medications Development Committee), and NIDA-K (Training Committee). Three Special Emphasis Panels were held to review applications in conflict with the chartered committees. Five Special Emphasis Panels were constituted for reviews of specific mechanisms: centers, program projects (two meetings), institutional development programs, and conference grants. Two additional Special Emphasis Panels were required for specific applications. In addition, OEA staff managed the reviews for B/START and Cutting Edge Basic Research Award mechanisms.

The following RFA review meetings were held:

DA 01-004 The Transition from Drug Use to Addiction: Unearthing the Switch
DA 01-005 Health and Developmental Consequences of Prenatal Exposure to Methamphetamine
DA 01-006 International Studies of HIV/AIDS
DA 01-007 HIV/AIDS and Drug Use Among Adolescents
DA 01-008 Health Disparities: Drug Use and Its Adverse Behavioral, Social, and Medical Consequences
DA 01-009 The Next Generation of Drug Abuse Prevention Research
DA 01-010 Responding to Club Drugs and Other Emerging and Current Drug Abuse Trends
DA 01-014 Research on GHB and Its Precursors
DA 01-015 Therapeutic Community Research

The Contracts Review Branch managed the following reviews of proposals:

N44DA-1-5514 State and Local Epidemiological Planning
N01DA-1-2200 Pharmacy and Clinical Support to the Clinical Trials Network
N01DA-1-2201 Administrative Support Center to the Clinical Trials Network
N01DA-1-9902 Subject Recruitment for NIDA Intramural Research Program
N44DA-1-5502 SA Prevention Program - Phase II SBIR
N44DA-1-7701 Configure Gene Chips - Phase II SBIR
N01DA-1-8815 Synthesis Medicinal Chemistry
N01DA-1-8817 Pharmacokinetic Analysis Resource Center
N44DA-1-7700 JAVA Tool - MicroArrays
N01DA-1-1105 Research Dissemination
N01DA-1-1106 NIDA's Science Meetings Logistical Support
N01DA-1-8818 Regulatory Affairs Support

In addition a concept for SBIR contract project N43DA-2-7726, Functional Imaging Agents, was reviewed.

Staff Training and Policy Development

The OEA Symposium Series continued its monthly meetings for staff development. In May 2001, staff raised a number of items for discussion from the scheduled "open floor" forum. In June 2001, Dr. Karin Johnson, of NIDA's Center on AIDS and Other Medical Consequences of Drug Abuse (CAMCODA), presented on using the internet to provide ideas for NIDA activities. July 2001's meeting consisted of discussion of case studies, and August's meeting centered on a discussion of bioethics, led by Mr. Noble Jones, CAMCODA. In August 2001, Dr. Mark Swieter, SRA in the Basic Science Review Branch, OEA, assumed responsibility for organization of the OEA Symposium Series.

Dr. Teresa Levitin, Director, OEA, and Ms. Loretta Beuchert, Program Assistant, OEA, are compiling comments reviewers made about their participation in the Cutting-edge Basic Research Award (CEBRA) initiative. These comments will provide guidance as future procedures and policies related to CEBRA are developed.

[Office of the Director][Report Index][Next Report Section]

Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal